CHF8.50
6.65%
SIX Swiss Exchange, Oct 20, 05:30 pm CEST. Closed.
ISIN
IT0004147952
Symbol
NWRN

Newron Pharmaceutical Target price 2026 - Analyst rating & recommendation

Newron Pharmaceutical Classifications & Recommendation

Buy
91%
Hold
9%

Newron Pharmaceutical Price Target

Target Price CHF35.70
Price CHF8.50
Potential
Number of Estimates 8
8 Analysts have issued a price target Newron Pharmaceutical 2027 . The average Newron Pharmaceutical target price is CHF35.70. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 11 analysts: 10 Analysts recommend Newron Pharmaceutical to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Newron Pharmaceutical stock has an average upside potential 2027 of . Most analysts recommend the Newron Pharmaceutical stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Revenue Million CHF ??? ???
??? ???
EBITDA Margin ??? ???
??? ???
Net Margin ??? ???
??? ???

8 Analysts have issued a sales forecast Newron Pharmaceutical 2026 . The average Newron Pharmaceutical sales estimate is

. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .

This results in the following potential growth metrics:

Revenue Estimates

2025 CHF17.7m 62.78%
2026
2027
2028
2029
2030
2031
2032
2033

5 Analysts have issued an Newron Pharmaceutical EBITDA forecast 2026. The average Newron Pharmaceutical EBITDA estimate is

. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 CHF-4.2m 117.15%
2026
2027
2028
2029
2030
2031
2032
2033

EBITDA Margin

2025 -23.63% 146.07%
2026
2027
2028
2029
2030
2031
2032
2033

8 Newron Pharmaceutical Analysts have issued a net profit forecast 2026. The average Newron Pharmaceutical net profit estimate is

. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 CHF-12.3m 183.58%
2026
2027
2028
2029
2030
2031
2032
2033

Net Margin

2025 -69.20% 324.54%
2026
2027
2028
2029
2030
2031
2032
2033

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share CHF ??? ???
??? ???
P/E ???
EV/Sales ???

8 Analysts have issued a Newron Pharmaceutical forecast for earnings per share. The average Newron Pharmaceutical EPS is

. This is than earnings per share in the financial year 2025. The highest EPS forecast is , the lowest is .

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 CHF-0.61 177.22%
2026
2027
2028
2029
2030
2031
2032
2033

P/E ratio

Current -13.07 176.91%
2026
2027
2028
2029
2030
2031
2032
2033

Based on analysts' sales estimates for 2026, the Newron Pharmaceutical stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 10.31 53.88%
2026
2027
2028
2029
2030
2031
2032
2033

P/S ratio

Current 9.82 66.22%
2026
2027
2028
2029
2030
2031
2032
2033

Current Newron Pharmaceutical Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
???
Locked
➜
Locked
Locked ???
???
Locked
➜
Locked
Locked ???
???
Locked
➜
Locked
Locked ???
???
Locked
➜
Locked
Locked ???
???
Locked
➜
Locked
Locked ???
???
Locked
➜
Locked
Locked ???
???
Locked
➜
Locked
Locked ???
Analyst Rating Date
Locked
???:
Locked
➜
Locked
???
Locked
???:
Locked
➜
Locked
???
Locked
???:
Locked
➜
Locked
???
Locked
???:
Locked
➜
Locked
???
Locked
???:
Locked
➜
Locked
???
Locked
???:
Locked
➜
Locked
???
Locked
???:
Locked
➜
Locked
???

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today